title: Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy.
abstract: The neuregulin-1 (NRG1)/ErbB system has emerged as a paracrine endothelium-controlled system in the heart, which preserves left ventricular (LV) performance in pathophysiological conditions. Here, we analyze the activity and function of this system in pregnancy, which imparts a physiological condition of LV hemodynamic overload. NRG1 expression and ErbB receptor activation were studied by Western blot analyses in rats and mice at different stages of pregnancy. LV performance was evaluated by transthoracic echocardiography, and myocardial performance was assessed from twitches of isolated papillary muscles. NRG1/ErbB signaling was inhibited by oral treatment of animals with the dual ErbB1/ErbB2 tyrosine kinase inhibitor lapatinib. Analyses of LV tissue revealed that protein expression of different NRG1 isoforms and levels of phosphorylated ErbB2 and ErbB4 significantly increased after 1-2 wk of pregnancy. Lapatinib prevented phosphorylation of ErbB2 and ERK1/2, but not of ErbB4 and protein kinase B (Akt), revealing that lapatinib only partially inhibited NRG1/ErbB signaling in the LV. Lapatinib did not prevent pregnancy-induced changes in LV mass and did not cause apoptotic cell death or fibrosis in the LV. Nevertheless, lapatinib led to premature maternal death of ∼25% during pregnancy and it accentuated pregnancy-induced LV dilatation, significantly reduced LV fractional shortening, and induced abnormalities of twitch relaxation (but not twitch amplitude) of isolated papillary muscles. This is the first study showing that the NRG1/ErbB system is activated, and plays a modulatory role, during physiological hemodynamic overload associated with pregnancy. Inhibiting this system during physiological overload may cause LV dysfunction in the absence of myocardial cell death.
authors.affiliation: Laboratory of Physiology, University of Antwerp, Antwerp, Belgium. katrien.lemmens@ua.ac.be
authors.forename: Katrien
authors.initials: K
authors.lastname: Lemmens
authors.forename: Kris
authors.initials: K
authors.lastname: Doggen
authors.forename: Gilles W
authors.initials: GW
authors.lastname: De Keulenaer
mesh_terms: D000818:Animals; D005260:Female; D018815:Genes, erbB / Q000187:drug effects* / Q000502:physiology*; D000077341:Lapatinib; D051379:Mice; D008810:Mice, Inbred C57BL; D020890:Neuregulin-1 / Q000502:physiology*; D010766:Phosphorylation; D011247:Pregnancy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000494:pharmacology; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D011799:Quinazolines / Q000009:adverse effects / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D016277:Ventricular Function, Left / Q000502:physiology*; D020257:Ventricular Remodeling / Q000187:drug effects* / Q000502:physiology*
chemical_list: D020890:Neuregulin-1; C490581:Nrg1 protein, mouse; C490580:Nrg1 protein, rat; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077341:Lapatinib; D051057:Proto-Oncogene Proteins c-akt